12/22/2008 | SS | Investor Alan Powers reports passive stake of 19.5% in Genitope
|
10/19/2007 | CVHY | Genitope files $125 million shelf
|
10/9/2007 | PP | New Issue: Genitope to raise $2,025,000 in direct placement
|
10/9/2007 | PP | Market Commentary: Dynamotive wraps $10.5 million equity financing; QGX closes C$3 million tranche; Longford sells C$2.2 million
|
11/9/2006 | BT | Genitope says funds sufficient through end of 2007
|
9/11/2006 | BT | Market Commentary: Genentech falls on Avastin delay; Vertex pitches $300 million deal; OSI off 2%; Genitope loses 5%
|
8/17/2006 | BT | Genitope says phase 3 data for MyVax similar to phase 2 findings; Kaplan-Meier curve not as expected
|
8/17/2006 | BT | Genitope reiterated at sector perform
|
8/17/2006 | BT | Market Commentary: Neurocrine adds 10%; NPS up on 'Soros factor'; Vivus higher; Genitope slides 4%
|
8/11/2006 | BT | RBC picks Gilead, Adolor as biotech underperforms for 2006 to date
|
8/7/2006 | BT | Market Commentary: Encysive sinks on dilution worries; Acorda higher; Genitope gains; Ariad off
|
8/1/2006 | BT | Market Commentary: ViroPharma spikes ahead of 2Q; Genomic off on lower outlook; Genitope falls 12% on new data
|
7/28/2006 | BT | Genitope: Safety board recommends MyVax trial for lymphoma continue
|
7/28/2006 | BT | RBC downgrades Genitope to sector perform
|
7/28/2006 | BT | Market Commentary: Genitope crashes; Biomet firms; Dynavax tumbles; Nymox gains; Napo debut in London next week
|
7/24/2006 | BT | Market Commentary: Genitope falls 12%; Micromet off; Oscient up; DepoMed dives; Atricure off; Discovery Labs rises 10%
|
7/17/2006 | BT | Market Commentary: Threshold plunges over 51%; Genitope firms; Vivus dives; Progenics weak; Alnylam off
|
7/17/2006 | BT | RBC rates Genitope at outperform
|
6/13/2006 | BT | Genitope's MyVax lymphoma therapy granted fast-track status
|
6/13/2006 | BT | Market Commentary: Lexicon drops 5%; Genitope stays steady; Vivus, Arena decline amid their respective obesity drug news
|
4/21/2006 | BT | Market Commentary: Omrix settles above water but on deep-discount pricing; Affymetrix plunges 14%; Genitope gains 3%
|
3/31/2006 | BT | Market Commentary: NitroMed restructuring cheered; Genitope gains on MyVax data; ZymoGenetics up; Panacos off
|
3/31/2006 | BT | Genitope gets data safety monitoring board approval to continue MyVax clinical trial
|
3/31/2006 | BT | Genitope reports fourth-quarter, year-end losses
|
2/27/2006 | BT | Genitope starts clinical trial to evaluate lymphocytic leukemia drug MyVax
|
2/17/2006 | BT | Genitope greenshoe exercised, raising follow-on sale to $62.56 million
|
2/7/2006 | BT | Market Commentary: Alexion hits new high; Vertex up on data, earnings; Genitope lifted after deal; Oscient up on new pact
|
2/7/2006 | BT | New Issue: Genitope raises $54.4 million in follow-on of 6.4 million shares at $8.50 vs. $8.93 close
|
1/24/2006 | BT | Market Commentary: Nuvelo, Tercica toss hats in ring; Serono plunges on lack of suitors; Imclone results miss, seeks merger
|
1/23/2006 | BT | Genitope plans follow-on of 4.5 million shares via WR Hambrecht
|
1/23/2006 | BT | Market Commentary: Genitope shares fall nearly 10% on follow-on plans; Arena slides; SkyePharma up; MannKind drops
|
12/9/2005 | BT | Market Commentary: Adams slides after secondary; Voyager IPO delayed; Cephalon spikes, Teva rises; Genitope up
|
12/8/2005 | BT | Genitope files patents for personalized monoclonal anitbodies for non-Hodgkin's lymphoma
|
9/16/2005 | BT | Genitope files $125 million stock shelf
|
12/15/2004 | PP | New Issue: Genitope increases private placement of shares to $60.5 million
|
12/15/2004 | PP | Market Commentary: Private placement volume maintains on modest stock gains; Genitope raises $60.5 million
|
12/14/2004 | PP | Market Commentary: Private placement volume improves; First Avenue Networks wraps deal for $93.3 million
|
12/14/2004 | PP | New Issue: Genitope plans to raise $57 million in private placement of shares
|